Your browser doesn't support javascript.
loading
Human(ized) monoclonal antibodies in atopic patients - state of the art.
Yalcin, Arzu Didem; Onbasi, Kevser; Uzun, Rusen; Herth, Felix; Schnabel, Philipp Albert.
Afiliación
  • Yalcin AD; Department of Internal Medicine, Allergy and Clinical Immunology, Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Onbasi K; Department of Allergy and Clinical Immunology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey.
  • Uzun R; Department of Internal Medicine, Allergy and Clinical Immunology, Dumlupinar University, Kütahya, Turkey.
  • Herth F; Department of Pulmonology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey.
  • Schnabel PA; Department of Pulmonary and Critical Care Medicine, Thoraxklinik Translational Lung Research Center, University of Heidelberg, Heidelberg, Germany.
Cent Eur J Immunol ; 45(2): 195-201, 2020.
Article en En | MEDLINE | ID: mdl-33456331
Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cent Eur J Immunol Año: 2020 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Polonia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cent Eur J Immunol Año: 2020 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Polonia